{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:29:51Z","timestamp":1774438191150,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03185-0","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:53:08Z","timestamp":1760093588000},"page":"286-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of clopidogrel monotherapy versus aspirin monotherapy after percutaneous coronary intervention"],"prefix":"10.1007","volume":"59","author":[{"given":"Saad Ahmed","family":"Waqas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Imran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdur Rafay","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzaib","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hateem","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas W. S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"3185_CR1","unstructured":"Ahmad M, Mehta P, Reddivari AKR, Mungee S (2025) Percutaneous Coronary Intervention. In: StatPearls. StatPearls Publishing; Accessed April 16, 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556123\/"},{"key":"3185_CR2","unstructured":"GBD Results. Institute for Health Metrics and Evaluation. Accessed April 16 (2025) https:\/\/vizhub.healthdata.org\/gbd-results"},{"issue":"4","key":"3185_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41569-018-0118-5","volume":"16","author":"T Gori","year":"2019","unstructured":"Gori T, Polimeni A, Indolfi C, R\u00e4ber L, Adriaenssens T, M\u00fcnzel T (2019) Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol 16(4):243\u2013256. https:\/\/doi.org\/10.1038\/s41569-018-0118-5","journal-title":"Nat Rev Cardiol"},{"key":"3185_CR4","doi-asserted-by":"publisher","unstructured":"Sv R, Ml O (2025) 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 151(13). https:\/\/doi.org\/10.1161\/CIR.0000000000001309","DOI":"10.1161\/CIR.0000000000001309"},{"issue":"17","key":"3185_CR5","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","volume":"17","author":"DJ Angiolillo","year":"2022","unstructured":"Angiolillo DJ, Galli M, Collet JP, Kastrati A, O\u2019Donoghue ML (2022) Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 17(17):e1371\u2013e1396. https:\/\/doi.org\/10.4244\/EIJ-D-21-00904","journal-title":"EuroIntervention"},{"key":"3185_CR6","doi-asserted-by":"publisher","first-page":"107602962412447","DOI":"10.1177\/10760296241244772","volume":"30","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhou D, Song S, Huang X, Ding Y, Meng R (2024) Efficacy and safety of long-term dual antiplatelet therapy: a systematic review and meta-analysis. Clin Appl Thromb Hemost 30:10760296241244772. https:\/\/doi.org\/10.1177\/10760296241244772","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"3185_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","volume":"9","author":"Y Li","year":"2024","unstructured":"Li Y, Li J, Wang B et al (2024) Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: the OPT-BIRISK randomized clinical trial. JAMA Cardiol 9(6):523\u2013531. https:\/\/doi.org\/10.1001\/jamacardio.2024.0534","journal-title":"JAMA Cardiol"},{"issue":"8","key":"3185_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/eurheartj\/ehn417","volume":"30","author":"SS Jolly","year":"2009","unstructured":"Jolly SS, Pogue J, Haladyn K et al (2009) Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 30(8):900\u2013907. https:\/\/doi.org\/10.1093\/eurheartj\/ehn417","journal-title":"Eur Heart J"},{"issue":"22","key":"3185_CR9","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garc\u00eda Rodr\u00edguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353(22):2373\u20132383. https:\/\/doi.org\/10.1056\/NEJMra052717","journal-title":"N Engl J Med"},{"issue":"16","key":"3185_CR10","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","volume":"14","author":"SJ Hong","year":"2021","unstructured":"Hong SJ, Kim JS, Hong SJ et al (2021) 1-month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial. JACC Cardiovasc Interv 14(16):1801\u20131811. https:\/\/doi.org\/10.1016\/j.jcin.2021.06.003","journal-title":"JACC Cardiovasc Interv"},{"key":"3185_CR11","doi-asserted-by":"publisher","first-page":"1265983","DOI":"10.3389\/fcvm.2023.1265983","volume":"10","author":"D Liu","year":"2023","unstructured":"Liu D, Xu WP, Xu H, Zhao L, Jin DQ (2023) Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis. Front Cardiovasc Med 10:1265983. https:\/\/doi.org\/10.3389\/fcvm.2023.1265983","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"3185_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3390\/biom14101329","volume":"14","author":"L Cappannoli","year":"2024","unstructured":"Cappannoli L, Colantuono S, Animati FM et al (2024) Aspirin hypersensitivity in patients with coronary artery disease: an updated review and practical recommendations. Biomolecules 14(10):1329. https:\/\/doi.org\/10.3390\/biom14101329","journal-title":"Biomolecules"},{"issue":"18","key":"3185_CR13","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.jacc.2024.05.084","volume":"84","author":"M Galli","year":"2024","unstructured":"Galli M, Cortellini G, Occhipinti G, Rossini R, Romano A, Angiolillo DJ (2024) Aspirin hypersensitivity in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol 84(18):1748\u20131766. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.084","journal-title":"J Am Coll Cardiol"},{"issue":"10486","key":"3185_CR14","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","volume":"405","author":"KH Choi","year":"2025","unstructured":"Choi KH, Park YH, Lee JY et al (2025) Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet 405(10486):1252\u20131263. https:\/\/doi.org\/10.1016\/S0140-6736(25)00449-0","journal-title":"Lancet"},{"key":"3185_CR15","unstructured":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews | The BMJ. Accessed April 16 (2025) https:\/\/www.bmj.com\/content\/372\/bmj.n160.short"},{"key":"3185_CR16","unstructured":"RoB 2: a revised tool for assessing risk of bias in randomised trials | The BMJ. Accessed April 16 (2025) https:\/\/www.bmj.com\/content\/366\/bmj.l4898"},{"issue":"4","key":"3185_CR17","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719\u2013748","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"3185_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR (2018) A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc 16(4):195\u2013203. https:\/\/doi.org\/10.1097\/XEB.0000000000000141","journal-title":"Int J Evid Based Healthc"},{"issue":"8","key":"3185_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101174","volume":"48","author":"BEX Tan","year":"2023","unstructured":"Tan BEX, Wong PY, Baibhav B et al (2023) Clopidogrel vs aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and meta-analysis. Curr Probl Cardiol 48(8):101174. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101174","journal-title":"Curr Probl Cardiol"},{"key":"3185_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00449-0","author":"KH Choi","year":"2025","unstructured":"Choi KH, Park YH, Lee JY et al (2025) Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(25)00449-0","journal-title":"Lancet"},{"issue":"47","key":"3185_CR21","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1093\/eurheartj\/ehae617","volume":"45","author":"H Watanabe","year":"2024","unstructured":"Watanabe H, Natsuaki M, Morimoto T et al (2024) Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial. Eur Heart J 45(47):5042\u20135054. https:\/\/doi.org\/10.1093\/eurheartj\/ehae617","journal-title":"Eur Heart J"},{"key":"3185_CR22","unstructured":"Adenosine Diphosphate Receptor Inhibitor - an overview | ScienceDirect Topics. Accessed April 7 (2025) https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/adenosine-diphosphate-receptor-inhibitor"},{"issue":"4","key":"3185_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","volume":"72","author":"TD Warner","year":"2011","unstructured":"Warner TD, Nylander S, Whatling C (2011) Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 72(4):619\u2013633. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03943.x","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3185_CR24","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/01.cir.75.5.1025","volume":"75","author":"PA Kyrle","year":"1987","unstructured":"Kyrle PA, Eichler HG, J\u00e4ger U, Lechner K (1987) Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation 75(5):1025\u20131029. https:\/\/doi.org\/10.1161\/01.cir.75.5.1025","journal-title":"Circulation"},{"issue":"11","key":"3185_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11906-016-0688-8","volume":"18","author":"MS Dzeshka","year":"2016","unstructured":"Dzeshka MS, Shantsila A, Lip GYH (2016) Effects of aspirin on endothelial function and hypertension. Curr Hypertens Rep 18(11):83. https:\/\/doi.org\/10.1007\/s11906-016-0688-8","journal-title":"Curr Hypertens Rep"},{"issue":"4","key":"3185_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.14797\/mdcvj.293","volume":"17","author":"E Murphy","year":"2021","unstructured":"Murphy E, Curneen JMG, McEvoy JW (2021) Aspirin in the modern era of cardiovascular disease prevention. Methodist Debakey Cardiovasc J 47. https:\/\/doi.org\/10.14797\/mdcvj.293","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"14","key":"3185_CR27","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 42(14):1289\u20131367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"issue":"1","key":"3185_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacc.2023.10.013","volume":"83","author":"H Watanabe","year":"2024","unstructured":"Watanabe H, Morimoto T, Natsuaki M et al (2024) Clopidogrel vs aspirin monotherapy beyond 1 year after percutaneous coronary intervention. J Am Coll Cardiol 83(1):17\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.013","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3185_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ahj.2008.08.031","volume":"157","author":"KH Mak","year":"2009","unstructured":"Mak KH, Bhatt DL, Shao M (2009) Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) study. Am Heart J 157(4):658\u2013665. https:\/\/doi.org\/10.1016\/j.ahj.2008.08.031","journal-title":"Am Heart J"},{"issue":"6","key":"3185_CR30","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/01.STR.0000221714.96986.5f","volume":"37","author":"A Kitamura","year":"2006","unstructured":"Kitamura A, Nakagawa Y, Sato M et al (2006) Proportions of stroke subtypes among men and women\u2009>\u2009or =\u200940 years of age in an urban Japanese City in 1992, 1997, and 2002. Stroke 37(6):1374\u20131378. https:\/\/doi.org\/10.1161\/01.STR.0000221714.96986.5f","journal-title":"Stroke"},{"issue":"8","key":"3185_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4070\/kcj.2020.0098","volume":"50","author":"H Cho","year":"2020","unstructured":"Cho H, Kang J, Kim HS, Park KW (2020) Ethnic differences in oral antithrombotic therapy. Korean Circ J 50(8):645\u2013657. https:\/\/doi.org\/10.4070\/kcj.2020.0098","journal-title":"Korean Circ J"},{"issue":"10293","key":"3185_CR32","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","volume":"397","author":"BK Koo","year":"2021","unstructured":"Koo BK, Kang J, Park KW et al (2021) Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 397(10293):2487\u20132496. https:\/\/doi.org\/10.1016\/S0140-6736(21)01063-1","journal-title":"Lancet"},{"key":"3185_CR33","unstructured":"PCI or CABG in Stable Patients With Multivessel CAD and Diabetes. American College of Cardiology. Accessed April 7 (2025) https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2018\/03\/27\/08\/51\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2018%2f03%2f27%2f08%2f51%2fPCI-or-CABG-in-Stable-Patients-With-Multivessel-CAD-and-Diabetes"},{"key":"3185_CR34","unstructured":"Diabetes and Heart Disease. November 6 (2023) Accessed April 7, 2025. https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/diabetes\/diabetes-and-heart-disease"},{"key":"3185_CR35","unstructured":"Dean L, Kane M (2012) Clopidogrel Therapy and CYP2C19 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, eds. Medical Genetics Summaries. National Center for Biotechnology Information (US); Accessed August 18, 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK84114\/"},{"issue":"7","key":"3185_CR36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jacasi.2025.04.010","volume":"5","author":"Y Gong","year":"2025","unstructured":"Gong Y, Jeong YH, Wang TD et al (2025) Position statement on antiplatelet therapy for East Asians with coronary artery disease. JACC: Asia 5(7):821\u2013846. https:\/\/doi.org\/10.1016\/j.jacasi.2025.04.010","journal-title":"JACC: Asia"},{"issue":"2","key":"3185_CR37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11239-021-02543-y","volume":"53","author":"F Condello","year":"2022","unstructured":"Condello F (2022) Uncertainties about platelet function and genetic testing for guiding dual antiplatelet therapy in percutaneous coronary intervention. J Thromb Thrombolysis 53(2):514\u2013516. https:\/\/doi.org\/10.1007\/s11239-021-02543-y","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"3185_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031238","volume":"12","author":"F Condello","year":"2023","unstructured":"Condello F, Spaccarotella C, Sorrentino S, Indolfi C, Stefanini GG, Polimeni A (2023) Stent thrombosis and restenosis with contemporary drug-eluting stents: predictors and current evidence. J Clin Med 12(3):1238. https:\/\/doi.org\/10.3390\/jcm12031238","journal-title":"J Clin Med"},{"key":"3185_CR39","doi-asserted-by":"publisher","unstructured":"Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome | Circulation. Accessed April 7 (2025) https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.045695","DOI":"10.1161\/CIRCULATIONAHA.120.045695"},{"issue":"23","key":"3185_CR40","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","volume":"134","author":"G Gargiulo","year":"2016","unstructured":"Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M (2016) A critical appraisal of aspirin in secondary prevention. Circulation 134(23):1881\u20131906. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023952","journal-title":"Circulation"},{"issue":"1","key":"3185_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4244\/EIJ-D-16-00497","volume":"13","author":"R Piccolo","year":"2017","unstructured":"Piccolo R, Magnani G, Ariotti S et al (2017) Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. EuroIntervention 13(1):78\u201386. https:\/\/doi.org\/10.4244\/EIJ-D-16-00497","journal-title":"EuroIntervention"},{"key":"3185_CR42","unstructured":"Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2. American College of Cardiology. Accessed April 7 (2025) https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2019\/03\/17\/00\/01\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fClinical-Trials%2f2019%2f03%2f17%2f00%2f01%2fSTOPDAPT-2"},{"key":"3185_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062770","author":"J Kang","year":"2023","unstructured":"Kang J, Park KW, Lee H (2023) Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062770","journal-title":"Circulation"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03185-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03185-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03185-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:23:43Z","timestamp":1774427023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03185-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3185"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03185-0","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Greene has received research support from the Duke University Department of Medicine Chair\u2019s Research Award, American Heart Association, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Otsuka, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Eli Lilly, Lexicon, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Sumitomo Pharma, and Tricog Health; and has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, Novo Nordisk, and Roche Diagnostics. Dr. Khan has received fees from Bayer, Boehringer Ingelheim, and Novartis. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}